Cefonicid is a new parenteral cephalosporin antibiotic. Similar to other second-generation cephalosporins, cefonicid has excellent in vitro activity against gram-positive bacteria and many aerobic gram-negative bacteria. Previous clinical studies are few, but good responses have been seen with gonococcal urethritis and community-acquired pneumonia (4, 14) . Cefonicid has very high serum levels after infusion and a prolonged half-life (4.8 h) allowing for once-daily dosing. These characteristics suggest a role for cefonicid in the treatment of soft-tissue infections.
Patients with skin and soft-tissue infections admitted to Laboratory evaluation on admission included urinalysis, direct and indirect Coombs test, alkaline phosphatase, blood urea nitrogen, creatinine, creatinine phosphokinase, serum glutamic oxalacetic transaminase, bilirubin, and complete blood count. Laboratory evaluation was repeated every 3 days during therapy and after the completion of treatment. Patients were followed for 7 days after completion of therapy.
Twenty patients received the minimum 5 days of therapy (range, 5 to 7 days) and were judged evaluable. The mean age was 25 years, and 14 of 20 (70%) patients were male. Eighteen patients received intravenous therapy, and two received intramuscular therapy with cefonicid. Patients presented most frequently with cellulitis (16 cases). Other presentations were extremity ulcers with surrounding infection (two cases) and VOL. 23, 1983 N pyoderma (two cases 794, 1982) . Cefonicid is shown here to be relatively nontoxic, with minor side effects. Pain on intramuscular injection is a common occurrence with some cephalosporins (8) and, with cefonicid, may have been related to the large volume (5 ml) required to administer the single daily dose. This side effect may limit the intramuscular route of administration. Positive Coombs tests have been detected in 10 to 15% of patients treated with cephalosporins (9) , and its detection here in a single case is not surprising. Mild and transient elevation of serum transaminase has been described frequently with cephalosporin administration in the past (5, 13) . Its occurrence in 10%o of patients confirms prior observations that it is infrequent.
The effectiveness of cefonicid has been documented in several infections to be equivalent to that of commonly used parenteral antibiotics. Wallace and co-workers have documented the efficacy of cefonicid in community-acquired pneumonia (14) . All patients responded, and no serious adverse effects were reported. Prolonged therapeutic serum levels were documented, thus allowing once-daily dosing. In a study in which single doses of penicillin and cefonicid were compared for gonococcal urethritis, Duncan Cefonicid appears to offer major advantages over other second-generation cephalosporins. The convenience of once-daily dosing has the potential for substantial cost savings, with less nursing time required for drug administration and decreased use of certain nonrenewable resources, such as syringes and intravenous fluid and tubing. Patients with certain chronic infections requiring parenteral antibiotics may be able to leave the hospital environment sooner and receive treatment in an outpatient setting, with once-daily injections in a physician's office. This will reduce the opportunity for colonization with resistant hospital pathogens and return patients to employment sooner. Additional studies should be conducted to document the feasibility and potential economy of cefonicid use in the outpatient setting.
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